引言嵌合抗原受体 T 细胞（CAR-T）疗法改变了血液肿瘤的治疗格局[1]，其早期不良反应如细胞因子释放综合征（CRS）和神经毒性显著影响疗效和患者生存，受到临床广泛关注，管理与治疗方案也逐渐成熟[2]。而 CAR-T 治疗后的长期生存困境往往被忽视 ...

Single agent duvelisib demonstrated clinically meaningful response rates, including a substantial proportion of complete responses, in a heavily ...

Propensity score (PS) comparison between lisocabtagene maraleucel (liso-cel) plus ibrutinib combination therapy (combo) and liso-cel monotherapy (mono) cohorts from TRANSCEND CLL. This is an ASCO ...

Immix Biopharma Inc. (NASDAQ:IMMX) is one of the best performing NASDAQ stocks according to Wall Street analysts.

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 MagnetisMM-5 study evaluating ELREXFIO® ...

The objective response rate was 70%, with 45% of patients achieving a complete response or better. The Food and Drug Administration (FDA) has granted accelerated approval to Lynozyfic ™ (linvoseltamab ...

Patients with large B-cell lymphoma (LBCL) who had stable or progressive disease at the end of treatment or relapsed within 3 months had markedly worse response rates and survival outcomes than those ...

Elranatamab (Elrexfio; Pfizer) achieved the primary endpoint of progression-free survival (PFS) at a prespecified interim ...

ORLANDO, Fla. — Adding epcoritamab (Epkinly) to the standard-of-care (SOC) therapy of lenalidomide (Revlimid) and rituximab (Rituxan), a combination known as R 2, lowered the risk for disease ...